NEW YORK, Sept. 20, 2019 /PRNewswire/
-- Oppenheimer & Co. Inc. ("Oppenheimer") – a
leading investment bank, wealth manager, and a subsidiary of
Oppenheimer Holdings (NYSE: OPY) – will host its two-day Fall
Summit Focused on Specialty Pharma and Rare Disease Companies on
September 23-24, 2019 in New York. The event will feature panel
discussions and one-on-one meetings with companies specializing in
specialty pharma, orphan drug and rare disease therapies.
"We're incredibly proud to offer our clients access to leading
scientists and innovative firms spearheading development in the
Specialty Pharma and Rare Disease space," said Michael Margolis, R.Ph., Managing Director and
Co-Head of Healthcare Investment Banking. "There are tremendous
investment opportunities within this expanding industry. By
providing our clients with access to the companies involved with
these cutting-edge therapies we are helping them to make more
informed decisions."
Attending companies include Rocket Pharmaceuticals, ArQule,
Corbus Pharmaceuticals, GW Pharma, Global Blood Therapeutics,
Biohaven Pharmaceuticals, Catabasis, and Achillion Pharmaceuticals.
Additionally, the event will feature four panels, including:
- Treating CLL in the Age of Targeted Therapy with Kenneth R. Hoffman, MC, MPH, Medical Oncologist
with a private practice
- The Shifting HAE Treatment Landscape: Recent Developments and
Emerging Trends with Jonathan D.
Field, MD and Director of Pediatric Allergy at Beth Israel
Medical Center
- The Evolving Hyperlipidemia Treatment Landscape with
Eliot Brinton, MD, Director of
Atherometabolic Research at the Utah Foundation of Biomedical
Research and Kevin C. Maki, PhD,
President and Chief Scientist for the Midwest Biomedical
Research/Center for Metabolic and Cardiovascular Health in
Chicago
- The Emerging Regulatory Framework for Gene Therapy Development:
Recent Developments with James
Valentine, JD, MHS and associate at Hyman, Phelps &
McNamara, P.C.
"Specialty pharma plays a vital role in helping patients with
rare diseases or who require specialized medication," added
Erica L. Moffett, Managing Director
and Associate Director of Research at Oppenheimer. "By bringing
together innovative companies and sophisticated investors,
Oppenheimer is enabling an important dialogue and helping this
critical industry to continue growing."
Oppenheimer analysts attending the event to provide important
insights and industry perspective include:
- Matt Biegler, Senior Analyst
covering Emerging Biotechnology
- Mark Breidenbach, Ph.D.,
Executive Director and Senior Analyst covering Biotechnology
- Kevin DeGeeter, Managing
Director and Senior Analyst covering Biotechnology
- Leland Gershell, Managing
Director and Senior Analyst covering Biotechnology
- Justin Kim, Senior Analyst
covering Biotechnology
- Steven Lichtman, Managing
Director and Senior Analyst covering Medical Devices
- Jay Olson, Managing Director and
Senior Analyst covering Biopharmaceuticals
- Esther Rajavelu, Executive
Director and Senior Analyst covering Biotech and Specialty
Pharmaceuticals
- Hartaj Singh, Managing Director and Senior
Analyst covering Biotechnology
- Silvan Tuerkcan, Ph.D., Senior Analyst covering
Biotechnology
Upcoming Oppenheimer events include the Houston Oncology Summit
at the University of Texas MD Anderson
Cancer Center on October 17, 2019.
The event will feature lectures by notable scientists and
researchers, as well as presentations from innovative oncology
companies.
Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary
of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange),
and its affiliates provide a full range of wealth management,
securities brokerage and investment banking services to
high-net-worth individuals, families, corporate executives, local
governments, businesses and institutions.
View original
content:http://www.prnewswire.com/news-releases/oppenheimer-to-gather-leaders-scientists-and-investors-for-fall-summit-focused-on-specialty-pharma-and-rare-disease-companies-300922554.html
SOURCE Oppenheimer & Co. Inc.